12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Status:
Completed
Trial end date:
2017-01-31
Target enrollment:
Participant gender:
Summary
The hypothesis of this Phase 2, 12-week study, is that DS-8500a will improve glycemic control
relative to placebo, based on changes in HbA1c, with acceptable safety and tolerability, in
patients with Type 2 Diabetes Mellitus (T2DM) who are treated with metformin.